The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
CAR-T Therapies in Solid Tumors: Opportunities and Challenges
Open accessAbstract
Purpose of Review: This review will discuss the challenges facing chimeric antigen receptor (CAR)-T cell application for solid tumors and opportunities to overcome these obstacles. In addition, this review will examine therapies that are in development for pediatric solid tumors. Recent Findings: The similar success of CAR-T cell treatment for hematological malignancies has not been observed in solid tumors because of the hostile tumor microenvironment and tumor heterogeneity. Most strategies developed to combat these limitations emphasize combinatorial techniques that still require further testing. Preliminary results of multiple clinical trials, including GD2- and HER2-CAR-T cells, are encouraging but must be reproduced and validated on a larger scale. Summary: CAR-T cell application in solid tumors remains challenging, and most research is in development. Several clinical trials are ongoing for pediatric solid tumors. Early results are promising but demonstrate the need for CAR-T cell modification to prevent tumor recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004
CAR T Cell Therapy for Solid Tumors
Newick, K., O'Brien, S., Moon, E., & Albelda, S. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062315-120245 · Cited by 909
MyD88: a central player in innate immune signaling
Deguine, J., & Barton, G. M. (2014) · F1000Prime Reports · doi:10.12703/p6-97 · Cited by 692
CAR T cells in solid tumors: challenges and opportunities
Marofi, F., Motavalli, R., Safonov, V. A., Thangavelu, L., Yumashev, A. V., Alexander, M., Shomali, N., Chartrand, M. S., Pathak, Y., Jarahian, M., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-02128-1 · Cited by 582
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Mestermann, K., Giavridis, T., Weber, J., Rydzek, J., Frenz, S., Nerreter, T., Mades, A., Sadelain, M., Einsele, H., & Hudecek, M. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5907 · Cited by 531
Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity
Prinzing, B., Zebley, C. C., Petersen, C. T., Fan, Y., Anido, A. A., Yi, Z., Nguyen, P., Houke, H., Bell, M., Haydar, D., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abh0272 · Cited by 349
Xin, L., Gao, J., Zheng, Z., Chen, Y., Lv, S., Zhao, Z., Yu, C., Yang, X., & Zhang, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.648187 · Cited by 203
A Chimeric GM-CSF/IL18 Receptor to Sustain CAR T-cell Function
Lange, S., Sand, L. G. L., Bell, M., Patil, S. L., Langfitt, D., & Gottschalk, S. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0896 · Cited by 68
Mechanisms of T cell exhaustion guiding next-generation immunotherapy
Zebley, C. C., & Youngblood, B. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2022.04.004 · Cited by 65
Cited by
Barrett, A. M., Britton, Z. T., Carrasco, R. A., Breen, S., Broggi, M. A. S., Hatke, A. L., Clark, B., Yang, C., Phipps, S., Ortiz, L., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1853 · Cited by 43
Barata, A., Dhawale, T., Newcomb, R. A., Amonoo, H. L., Nelson, A. M., Yang, D., Karpinski, K., Holmbeck, K., Farnam, E., Frigault, M., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.01.063 · Cited by 13
Metadata
- Authors
- Guzman, G., Reed, M. R., Bielamowicz, K., Koss, B., & Rodriguez, A.
- Venue
- Current Oncology Reports
- Published
- 2023-02-28
- Volume
- 25
- Issue
- 5
- Pages
- 479-489
- ISSN
- 1523-3790 (ISSN-L)
- 1534-6269
- OpenAlex
- W4322617577
- Cited by
- 197
- References
- 11
- FWCI
- 20.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CAR-T Therapies in Solid Tumors: Opportunities and Challenges. https://app.cochat.ai/papers/10.1007/s11912-023-01380-x
- The paper
- Guzman, G., Reed, M. R., Bielamowicz, K., Koss, B., & Rodriguez, A. (2023). CAR-T Therapies in Solid Tumors: Opportunities and Challenges. Current Oncology Reports. https://doi.org/10.1007/s11912-023-01380-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.